相关实验视频
Updated: Jan 20, 2026

11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.8K
与GLP-1受体激素治疗相关的微量营养素和营养缺乏症:叙述性综述
Jorge Urbina1, Luis Eduardo Salinas-Ruiz2, César Valenciano1
1Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México.
Clinical obesity
|January 19, 2026
概括
类似葡萄糖-1受体激活剂 (GLP-1RA) 可能导致营养缺乏,包括维生素D,铁和的低水平. 使用GLP-1RA的患者应接受营养评估,以防止营养不良的风险.
科学领域:
- 内分泌学和新陈代谢学
- 营养科学 营养科学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 广泛用于2型糖尿病 (T2DM) 和肥胖症.
- 与GLP-1RA治疗相关的潜在微量营养素缺乏症需要临床调查,因为使用量增加.
研究的目的:
- 评估GLP-1RA治疗对成人营养和微量营养素状况的影响.
- 确定常见的缺陷,并评估相对于建议的摄入量.
主要方法:
- 对PubMed和Cochrane数据库 (2019年1月至2025年5月) 进行了结构化的文献搜索.
- 包括营养终点的成年人研究;排除了儿科研究,评论和缺乏特定结果措施的研究.
- 数据合成遵循SANRA和PRISMA-ScR指南,并进行描述性分析.
主要成果:
- 分析了六项涉及480,825名成年人的观察性研究.
- 维生素D缺乏是普遍存在的 (7.5%在6个月,13.6%在12个月).
- GLP-1RA使用者表现出较低的费里水平 (26-30%) 与SGLT2抑制剂相比;超过60%的和铁摄入量不足;维生素D摄入量为推的20%. 蛋白质和缺乏与瘦身量损失有关; 硫胺和胺缺乏随着时间的推移而增加.
结论:
- GLP-1RA治疗与显著的营养缺乏症有关,包括维生素D,铁,,蛋白质,胺和可巴胺.
- 建议针对高危患者进行有针对性的营养评估和实验室评估.
- 由于依赖观察数据,无法最终确定因果关系.
相关概念视频
11:45Quantifying Agonist Activity at G Protein-coupled Receptors
19.8K
A method for estimating the affinity constant of an agonist for the active state (Kb) of a G protein-coupled receptor is described. The analysis provides absolute or relative measures of Kb depending on whether constitutive receptor activation is measurable. Our method applies to various responses downstream from receptor...
19.8K
Key Elements for Plant Nutrition
24.0K
Like all living organisms, plants require organic and inorganic nutrients to survive, reproduce, grow and maintain homeostasis. To identify nutrients that are essential for plant functioning, researchers have leveraged a technique called hydroponics. In hydroponic culture systems, plants are grown—without soil—in water-based solutions containing nutrients. At least 17 nutrients have been identified as essential elements required by plants. Plants acquire these elements from the...
24.0K
Glucagon-like Receptor Agonists
856
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
856
Drug-Receptor Interaction: Agonist
4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
02:07Stimulation of Dorsal Root Ganglion Sensory Neurons Using a Neuropeptide Receptor Agonist
399
This video demonstrates the use of transfected dorsal root ganglion cells to study neurotransmitter release by stimulating them with a neuropeptide receptor...
399
08:11Measuring Caenorhabditis elegans Sensitivity to the Acetylcholine Receptor Agonist Levamisole
4.5K
The present protocol describes an assay to determine response to levamisole, a pharmacological agonist of one class of Caenorhabditis elegans acetylcholine receptors. In this liquid levamisole swim assay, researchers visually observe and quantitate the time-dependent paralysis of animals cultivated in 24-well plates.
4.5K
